P635 Carriage of the HLA-DQA1*05 allele is associated with a high risk of loss of response to infliximab in patients with inflammatory bowel disease

Editorial: is pharmacogenetic testing for adverse effects to IBD treatments ready for roll‐out?

“…In their cohort, the prevalence of TIP, TIM and immunogenicity to an anti‐TNFα was 4.2%, 5.5% and 23%, respectively. Significant associations were replicated for NUDT15 variants with TIM, HLA‐DQA1‐HLA‐DRB1 carriage with TIP, but not (unlike other cohorts) 6,7 HLA‐DQA1*05 carriage with the development of antibodies to anti‐TNFα. The apparent lack of an association is probably explained by the small numbers of patients treated with an anti‐TNFα and the limited availability of therapeutic drug monitoring data.…”

Human leukocyte antigens in inflammatory bowel disease

“…Similar results were obtained by our group in a cohort of 64 IBD patients with a primary response to infliximab. The presence of the HLA-DQA1 * 05 haplotype was independently associated with a higher probability of secondary loss of response (HR 3.5) 29 . These results were replicated in a cohort of 54 patients treated with adalimumab.…”